Insider Transactions in Q1 2022 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
David A Spellman SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
803
-0.62%
|
$1,606
$2.17 P/Share
|
|
Mar 01
2022
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
14,507
-1.55%
|
$29,014
$2.17 P/Share
|
|
Mar 01
2022
|
Dell Faulkingham SVP, CCO |
SELL
Open market or private sale
|
Direct |
6,705
-1.87%
|
$13,410
$2.17 P/Share
|
|
Mar 01
2022
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,978
-1.64%
|
$29,956
$2.17 P/Share
|
|
Mar 01
2022
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,656
-1.72%
|
$15,312
$2.17 P/Share
|
|
Mar 01
2022
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
53,973
-1.25%
|
$107,946
$2.17 P/Share
|
|
Feb 28
2022
|
David A Spellman SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+31.68%
|
-
|
|
Feb 28
2022
|
David A Spellman SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
7,400
-9.64%
|
$14,800
$2.15 P/Share
|
|
Feb 28
2022
|
Nicole R. Hadas SVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+13.67%
|
-
|
|
Feb 28
2022
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,555
-2.41%
|
$13,110
$2.15 P/Share
|
|
Feb 28
2022
|
Dell Faulkingham SVP, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+21.69%
|
-
|
|
Feb 28
2022
|
Dell Faulkingham SVP, CCO |
SELL
Open market or private sale
|
Direct |
6,479
-4.73%
|
$12,958
$2.15 P/Share
|
|
Feb 28
2022
|
Michel Dahan SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+13.93%
|
-
|
|
Feb 28
2022
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,555
-2.47%
|
$13,110
$2.15 P/Share
|
|
Feb 28
2022
|
Violetta Cotreau SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,833
+36.86%
|
-
|
|
Feb 28
2022
|
Violetta Cotreau SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,946
-11.93%
|
$7,892
$2.15 P/Share
|
|
Feb 28
2022
|
Steven Keith Burke SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+21.14%
|
-
|
|
Feb 28
2022
|
Steven Keith Burke SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,400
-4.32%
|
$14,800
$2.15 P/Share
|
|
Feb 28
2022
|
John P. Butler CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
293,125
+16.75%
|
-
|
|
Feb 28
2022
|
John P. Butler CEO and President |
SELL
Open market or private sale
|
Direct |
25,053
-2.11%
|
$50,106
$2.15 P/Share
|
|
Jan 03
2022
|
Violetta Cotreau SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,833
-14.99%
|
$11,666
$2.29 P/Share
|